Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

NCT06314490 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT06314490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06314490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A
Lead sponsor
University of California, San Diego
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 16, 2024
Completion date
February 16, 2026
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease